A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1, 2, 4]triazolo[4, 3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Group: Biochemicals. Alternative Names: 1- (4- (2- (4- (1- (3- (trifluoromethyl) -7, 8-dihydro-[1, 2, 4]triazolo[4, 3-b]pyridazin-6-yl) piperidin-4-yl) phenoxy) ethyl) piperazin-1-yl) ethanone; 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine. Grades: Highly Purified. CAS No. 1240299-33-5. Pack Sizes: 10mg, 25mg. Molecular Formula: C25H32F3N7O2, Molecular Weight: 519.56. US Biological Life Sciences. |  Worldwide |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Synonyms: AZD3514; AZD 3514; AZD-3514. Grades: 0.98. CAS No. 1240299-33-5. Molecular formula: C25H32F3N7O2. Mole weight: 519.56. |  |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Synonyms: AZD3759; AZD-3759; AZD 3759. Grades: 98%. CAS No. 1626387-80-1. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. | |
| AZD-3759 hydrochloride | AZD-3759 hydrochloride is an effective, orally active and central nervous system-penetrant EGFR inhibitor. AZD-3759 hydrochloride induces cancer cell apoptosis. Synonyms: AZD3759 hydrochloride; Zorifertinib HCl; Zorifertinib hydrochloride; (R)-4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride. CAS No. 1626387-81-2. Molecular formula: C22H24Cl2FN5O3. Mole weight: 496.36. | |
| AZD3839 | AZD3839, also called CHEMBL2177913, as a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the inhibition of BACE1 impedes the production of Aβ peptide. Synonyms: AZD3839; AZD-3839; AZD 3839. (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine; CHEMBL2177913; I8ID590133; UNII-I8ID590133; I8ID590133; SCHEMBL1358337; BDBM50398264; (1S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine; 1227163-84-9; 1H-Isoindol-3-amine, 1-(2-(difluoromethyl)-4-pyridinyl)-4-fluoro-1-(3-(5-pyrimidinyl)phenyl)-, (1S)-. CAS No. 1227163-84-9. Molecular formula: C24H16F3N5. Mole weight: 431.41. | |
| AZD3839 free base | AZD3839 free base is a potent and selective orally active, brain-permeable BACE1 inhibitor ( K i=26 nM). AZD3839 free base shows 14 and >1000-fold selectivity against BACE2 and cathepsin D, respectively. AZD3839 free base exhibits dose- and time-dependent lowering of plasma, brain, and cerebrospinal fluid Aβ levels in mouse, guinea pig, and non-human primate. AZD3839 free base can be used for the research of Alzheimer's disease [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1227163-84-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-13438. |  |
| AZD3965 | AZD3965 is a selective MCT1 inhibitor with a K i of 1.6 nM, showing 6-fold selectivity over MCT2. Uses: Scientific research. Group: Signaling pathways. CAS No. 1448671-31-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12750. | |
| AZD3965 | AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, which is 6-fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose- and time-dependent accumulation of lactate in the tumors, suppresses tumor growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine. The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers a novel mechanism for targeting the metabolic phenotype in tumors that preferentially express MCT1. Synonyms: (S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione; AZD3965; AZD-3965; AZD 3965. Grades: >98%. CAS No. 1448671-31-5. Molecular formula: C21H24F3N5O5S. Mole weight: 515.51. | |
| AZD3965 | AZD3965 Inhibitor. Uses: Scientific use. Product Category: T3210. CAS No. 1448671-31-5. |  |
| AZD 3988 | AZD 3988 is a selective and potent diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor with IC50 value of 0.6 nM. It is selective for DGAT-1 over DGAT-2, cytochrome P450 enzymes and Kv11.1 (hERG). It suppresses adipose tissue TAG synthesis and triacylglyceride (TAG) plasma excursion in rats. It reduces body weight of diet-induced obese rats and may be used as a potential treatment for diabetes and other metabolic diseases. It is orally bioavailable and cell permeable. Synonyms: AZD 3988; AZD-3988; AZD3988; trans-4- [- [ [ [5- [ (3, 4-Difluorophenyl) amino] -1, 3, 4-oxadiazol-2-yl] carbonyl] amino] phenyl] cyclohexaneacetic acid. Grades: ≥98% by HPLC. CAS No. 892489-52-0. Molecular formula: C23H22F2N4O4. Mole weight: 456.44. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable 11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Synonyms: AZD-4017; AZD 4017; (S)-2-(1-(5-(Cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid. Grades: 96%. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. AZD4017 is a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. AZD4017) is an effective inhibitor of 11β-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development. Group: Inhibitors. Alternative Names: AZD4017; AZD-4017; AZD 4017. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. Appearance: Solid powder. Purity: >98%. IUPACName: 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid. Canonical SMILES: O=C (O)C[C@H]1CN (C2=NC (SCCC)=C (C (NC3CCCCC3)=O)C=C2)CCC1. Catalog: ACM1024033439. |  |
| AZD4320 | AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC 50 s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1357576-48-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112416. | |
| AZD-4320 | AZD-4320 is a new type of BH3 analogue BCL2/BCLxL dual inhibitor. Synonyms: AZD4320. Grades: ≥98% by HPLC. CAS No. 1357576-48-7. Molecular formula: C45H48ClF3N4O7S3. Mole weight: 945.5. | |
| AZD-4547 | AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Synonyms: AZD-4547; AZD 4547; AZD4547; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide. Grades: 98%. CAS No. 1035270-39-3. Molecular formula: C26H33N5O3. Mole weight: 463.582. | |
| AZD4573 | AZD4573 is a potent and highly selective CDK9 inhibitor ( IC 50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2057509-72-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112088. | |
| AZD4573 | AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases. AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. Synonyms: AZD-4573; AZD 4573; (1S,3R)-3-acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexane-1-carboxamide. Grades: ≥98%. CAS No. 2057509-72-3. Molecular formula: C22H28ClN5O2. Mole weight: 429.94. | |
| AZD-4635 | AZD-4635 is an orally available adenosine 2A receptor (A2AR) inhibitor. Synonyms: AZD-4635; AZD 4635; AZD4635; HTL-1071; HTL 1071; HTL1071; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine. CAS No. 1321514-06-0. Molecular formula: C15H11ClFN5. Mole weight: 315.736. | |
| AZD-4694 | AZD-4694 is a bio-active chemical compound and is used as a diagnostic imaging agent. It was developed by AstraZeneca. Synonyms: AZD 4694; AZD-4694; AZD4694; NAV4694; NAV 4694; NAV-4694; Flutafuranol; 2-(2-Fluoro-6-methylaminopyridin-3-yl)benzofuran-5-ol. Grades: >98%. CAS No. 1054629-49-0. Molecular formula: C14H11FN2O2. Mole weight: 258.25. | |
| AZD4694 Precursor | AZD4694 Precursor (AZ13040214) is the precursor of [ 18 F] AZD4694 for the synthesis of [ 18 F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AZ13040214; NAV4614. CAS No. 1211333-20-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139516. | |
| AZD-4818 | AZD-4818 is a chemokine CCR1 antagonist that is used for the treatment of chronic obstructive pulmonary disease. Group: Antagonists. Alternative Names: AZD-4818; AZD 4818; AZD4818. CAS No. 1003566-93-5. Molecular formula: C27H32Cl2N2O7. Mole weight: 567.46. Appearance: Solid powder. Purity: >98%. IUPACName: (S)-2-(2-chloro-5-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropoxy)-4-(methylcarbamoyl)phenoxy)-. Canonical SMILES: CC (C) (OC1=CC (OC[C@@H] (O)CN2CCC3 (CC2)OC4=CC=C (Cl)C=C4C3)=C (C (NC)=O)C=C1Cl)C (O)=O. Catalog: ACM1003566935. | |
| AZD4877 | AZD4877 is a synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which may result in the inhibition of mitotic spindle assembly. Synonyms: AZD-4877; AZD 4877; (+)-N-(3-Aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide. CAS No. 1176760-49-8. Molecular formula: C28H33N5O2S. Mole weight: 503.66. | |
| AZD-5069 | AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. AZD-5069 was shown to inhibit binding of radiolabeled CXCL8 to human CXCR2 with a pIC50 value of 9.1. Synonyms: AZD-5069; AZD 5069; AZD5069. Grades: 98%. CAS No. 878385-84-3. Molecular formula: C18H22F2N4O5S2. Mole weight: 476.51. | |
| AZD-5099 | AZD-5099 is a DNA gyrase modulator potentially for the treatment of bacterial infection. Group: Others. Alternative Names: AZD-5099; AZD 5099; AZD5099. CAS No. 907543-25-3. Molecular formula: C21H27Cl2N5O6S. Mole weight: 548.44. Appearance: Solid powder. Purity: >98%. IUPACName: 2-((3S,4R)-4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-3-methoxypiperidin-1-yl)-4-(((S)-1-methoxypropan-2-yl)carbamoyl)thiazole-5-carboxylic acid. Canonical SMILES: O=C (C1=C (C (N[C@@H] (C)COC)=O)N=C (N2C[C@H] (OC)[C@H] (NC (C3=C (Cl)C (Cl)=C (C)N3)=O)CC2)S1)O. Catalog: ACM907543253. | |
| AZD5153 | AZD5153 (Compound 13) is a trivalent triazolpyrazine bromide domain (BRD), bromodomain and extraterminal (BET) inhibitor. AZD5153 has down-regulated c-Myc gene and tumor growth inhibition activity. AZD5153 can be used in the study of BET small molecule inhibitors [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1869912-39-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg. Product ID: HY-100653. | |
| AZD 5153 | AZD5153 is a potent, selective, and orally available inhibitor of the bromodomain and extraterminal (BET) Inhibitor. It can simultaneously bind two bromodomains in BRD4 with the IC50 value of 5 nM, which has been shown to increase antitumor activity in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B cell lymphoma. AZD5153 also shows enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency. Synonyms: (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidinyl]phenoxy]ethyl]-1,3-dimethyl-2-piperazinone; (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one. Grades: ≥ 95 %. CAS No. 1869912-39-9. Molecular formula: C25H33N7O3. Mole weight: 479.57. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid, a 6-hydroxy-2-naphthoic acid salt of AZD-5153, is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor possessing a bivalent binding mode (pKi = 8.3 for BRD4). Synonyms: AZD5153 6-Hydroxy-2-naphthoic acid; AZD 5153 6-Hydroxy-2-naphthoic acid; AZD-5153 6-Hydroxy-2-naphthoic acid; 6-hydroxynaphthalene-2-carboxylic acid;4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one. CAS No. 1869912-40-2. Molecular formula: C36H41N7O6. Mole weight: 667.75. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC 50 of 1.7 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1869912-40-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100653A. | |
| AZD5305 | AZD5305 is a potent, selective and oral active PARP inhibitor. AZD5305 is a highly potent inhibitor of PARP1, with significant PARP1-DNA trapping activity, no PARP2-activity, nor binding activity to any other members of the PARP family. AZD5305 has excellent secondary pharmacology and physicochemical properties as well as high oral bioavailability in preclinical species. Group: Inhibitors. Alternative Names: AZD5305; AZD-5305; AZD 5305. CAS No. 2589531-76-8. Molecular formula: C22H26N6O2. Mole weight: 406.49. Appearance: Solid powder. Purity: >98%. IUPACName: 5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide. Canonical SMILES: O=C (C1=NC=C (N2CCN (CC3=CC (N4)=C (N=C3)C=C (CC)C4=O)CC2)C=C1)NC. Catalog: ACM2589531768. | |
| AZD 5363 | AZD5363 is used in inhibiting the proliferation of certain tumor cell lines. Inhibits AKT1, AKT2, AKT3, P70S6K and PKA. Group: Biochemicals. Grades: Highly Purified. CAS No. 1143532-39-1. Pack Sizes: 1mg, 5mg. Molecular Formula: C21H25ClN6O2, Molecular Weight: 428.95. US Biological Life Sciences. | Worldwide |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Synonyms: AZD5363; AZD 5363; Capivasertib. Grades: 98%. CAS No. 1143532-39-1. Molecular formula: C21H25ClN6O2. Mole weight: 428.9152. | |
| AZD5423 | AZD5423 is an inhaled, potent, selective, and non-steroidal glucocorticoid receptor (GR) modulator (SGRM) [1]. AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1034148-04-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108243. | |
| AZD-5423 | AZD-5423 is a nonsteroidal glucocorticoid. It is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. It was developed by AstraZeneca. Uses: Azd-5423 is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. Synonyms: AZD-5423; AZD 5423; AZD5423; UNII-641H0Q518W; 2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide. Grades: >98 %. CAS No. 1034148-04-3. Molecular formula: C25H21F4N3O3. Mole weight: 487.45. | |
| AZD5438 | AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an effective method to impair the dysregulated cell cycle that drives tumorigenesis and AZD5438 has the pharmacologic profile that provides an ideal probe to test this premise. Synonyms: AZD5438; AZD-5438; AZD 5438. Grades: 0.98. CAS No. 602306-29-6. Molecular formula: C18H21N5O2S. Mole weight: 371.45664. | |
| AZD 5582 dihydrochloride | AZD 5582 dihydrochloride is a potent inhibitor of X-linked (XIAP) and cellular (cIAP) inhibitor of apoptosis protein. It can bind to the BIR3 domain of XIAP to prevent interaction with caspase-9. Synonyms: 3,3'-[2,4-Hexadiyne-1,6-diylbis[oxy[(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]]]bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolinamide. Grades: ≥97%. CAS No. 1883545-51-4. Molecular formula: C58H78N8O8·2HCl. Mole weight: 1088.21. | |
| AZD-5597 | AZD-5597 is a potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. AZD-5597 has excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel. Synonyms: AZD 5597; AZD5597; Methanone, [4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]-; [4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]methanone; (S)-(4-((5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(methylamino)pyrrolidin-1-yl)methanone. Grades: >98%. CAS No. 924641-59-8. Molecular formula: C23H28FN7O. Mole weight: 437.52. | |
| AZD-5672 | AZD5672 is CCR5 receptor antagonist originated by AstraZeneca. In Jul 2009, Phase-II for Rheumatoid arthritis in USA was discontinued. Uses: Rheumatoid arthritis. Synonyms: AZD-5672; AZD 5672; AZD5672; UNII-61XQN688TW; (R) -N- (1- (3- (3, 5-difluorophenyl) -3- (4- (methylsulfonyl) phenyl) propyl) piperidin-4-yl) -N-ethyl-2- (4- (methylsulfonyl) phenyl) acetamide. Grades: 98%. CAS No. 780750-65-4. Molecular formula: C32H38F2N2O5S2. Mole weight: 632.79. | |
| AZD-5904 | AZD-5904 is a potent orally bioavailable MPO inhibitor. It inhibited the isolated MPO enzyme with an IC50 value of 140 nM and was approximately equipotent in assays of rat and mouse MPO enzyme activity. It was used for multiple sclerosis and COPD and has been evaluated in single and multiple dose studies in healthy volunteers. Uses: Azd-5904 was used for multiple sclerosis and copd. Synonyms: AZ1, AZ 1 AZ-1; TX4; TX-4; TX 4; AZD-5904; AZD 5904; AZD5904. (S)-3-((tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one. Grades: 98%. CAS No. 618913-30-7. Molecular formula: C10H12N4O2S. Mole weight: 252.29. | |
| AZD5991 | AZD5991. Uses: For analytical and research use. Group: Impurity standards. CAS No. 2143010-83-5. Molecular Formula: C35H34ClN5O3S2. Mole Weight: 672.26. Catalog: APB2143010835. |  |
| AZD5991 | AZD5991 is a potent and selective Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay for treatment of hematologic cancers. AZD5991 has high selectivity and affinity for Mcl-1 and is currently in clinical development. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. AZD5991 monotherapy caused apoptosis preferentially in hematological cell lines with 6/22 AML and 7/19 MM cell lines showing caspase EC50 values <100 nM. In solid tumor cell lines single agent activity was seen mostly in NSCLC and BrCa. Uses: Antineoplastic agents. Synonyms: AZD-5991; AZD 5991; AZD-5991 Racemate; 22H-9, 4, 8-(Metheniminomethyno)-14, 20:26, 23-dimetheno-10H, 20H-pyrazolo[4, 3-l][2, 15, 22, 18, 19]benzoxadithiadiazacyclohexacosine-32-carboxylic acid, 5-chloro-2,11,12,24,27,29-hexahydro-2,3,24,33-tetramethyl-. Grades: ≥98%. CAS No. 2143010-83-5. Molecular formula: C35H34ClN5O3S2. Mole weight: 672.26. | |
| AZD-6126 | AZD6126 is a water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. Synonyms: AZD6126; AZD 6126; N-Acetylcochinol-O-phosphate; (5S)-5-acetamido-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-3-yl dihydrogen phosphate; N-[9,10,11-Trimethoxy-3-(phosphonooxy)-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl]ethanimidic acid. CAS No. 219923-05-4. Molecular formula: C20H24NO8P. Mole weight: 437.38. | |
| AZD-6280 | AZD-6280 is a selective GABAA(α2/3) receptor modulator for the treatment of generalized anxiety disorder. Synonyms: AZD6280; UNII-B9Z1OEH19D; AZD 6280; B9Z1OEH19D; CHEMBL1783256. Grades: 98%. CAS No. 942436-93-3. Molecular formula: C20H22N4O3. Mole weight: 366.4. | |
| Azd6482 | Heterocyclic Organic Compound. Alternative Names: 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid;(R)-2-(1-(7-Methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid;AZD 6482;AZD6482(PI3-kinase β inhibitor); AZD-6482/AZD6482; AZD6482(r); (R)AZD64822-[[(1R)-1-[7-Methyl-2-(4-Morpholinyl)-4-oxo-4h-pyrido[1, 2-a]pyriMidin-9-yl]ethyl]aMino]benzoic acid;KIN-193. CAS No. 1173900-33-8. Molecular formula: C22H24N4O4. Mole weight: 408.45036. Density: 1.36. Catalog: ACM1173900338. | |
| AZD6482 | AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3K&gamma. Phase 1. Synonyms: KIN193; AZD6482; KIN 193; AZD 6482; KIN-193; AZD-6482. Grades: >98%. CAS No. 1173900-33-8. Molecular formula: C22H24N4O4. Mole weight: 408.45. | |
| AZD6482 (S-isomer) | This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZD6482 also inhibited insulin-induced human adipocyte glucose uptake in vitro and IC50 value is 4.4 μm. In May 2008, AstraZeneca completed a phase I trial in Thrombosis in Sweden. In Jul 2010, Phase-I for Thrombosis in Sweden was discontinued. Uses: Thrombosis. Synonyms: AZD6482 (S-isomer); AZD 6482 (S-isomer); AZD-6482 (S-isomer); (S)-2-((1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid,1173900-33-8 (AZD6482). Grades: 98%. CAS No. 1173900-37-2. Molecular formula: C22H24N4O4. Mole weight: 408.46. | |
| AZD6738 | AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2. Synonyms: AZD-6738; AZD 6738. Grades: 98%. CAS No. 1352226-88-0. Molecular formula: C20H24N6O2S. Mole weight: 412.51. | |
| AZD7325 | AZD7325 is a potent and orally active partial selective PAM of GABAAα2 and Aα3 receptor ( K i =0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes [1] [4]. AZD7325 is a moderate CYP1A2 and a potent CYP3A4 inducer in vitro [2]. AZD7325 has the potential for the investigation of anxiety and dravet syndrome [3]. PAM: positive allosteric modulator. Uses: Scientific research. Group: Signaling pathways. CAS No. 942437-37-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-111052. | |
| AZD-7325 | AZD7325 is a high-affinity and selective modulator of the GABAA receptor system. Synonyms: AZD7325. Grades: 98%. CAS No. 942437-37-8. Molecular formula: C19H19FN4O2. Mole weight: 354.4. | |
| AZD7507 | AZD7507 is a CSF-1R inhibitor with anti-tumor activity. Synonyms: AZD-7507; AZD 7507. Grades: >98%. CAS No. 1041852-85-0. Molecular formula: C23H27FN6O3. Mole weight: 454.5. | |
| AZD7545 | AZD7545 is a potent PDHK inhibitor with IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2, respectively. Synonyms: AZD7545; AZD-7545; AZD 7545. Grades: >98%. CAS No. 252017-04-2. Molecular formula: C19H18ClF3N2O5S. Mole weight: 478.87. | |
| AZD-7594 | AZD-7594 is an inhaled selective glucocorticoid receptor (GCCR) modulator. Synonyms: AZD-7594; AZD 7594; AZD7594; AZ13189620; AZ-13189620; AZ 13189620; 3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]indazol-1-yl]-N-[(3R)-oxolan-3-yl]benzamide. CAS No. 1196509-60-0. Molecular formula: C32H32F2N4O6. Mole weight: 606.627. | |
| AZD7648 | AZD7648 is a potent and selective DNA-PK inhibitor with anti-tumor activity. Synonyms: AZD-7648; AZD 7648. Grades: 98%. CAS No. 2230820-11-6. Molecular formula: C18H20N8O2. Mole weight: 380.4. | |
| AZD7687 | AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). Synonyms: AZD7687; AZD 7687; AZD-7687. Grades: >98%. CAS No. 1166827-44-6. Molecular formula: C21H25N3O3. Mole weight: 367.44. | |
| AZD-7762 | AZD-7762 is a synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. Synonyms: AZD 7762; AZD7762. Grades: 0.98. CAS No. 860352-01-8. Molecular formula: C17H19FN4O2S. Mole weight: 362.423. | |
| AZD 7762 hydrochloride | AZD 7762 hydrochloride is the hydrochloride salt of AZD 7762, which is a selective and potent ATP-competitive inhibitor of Chk1 and Chk2 with IC50 values of 5 nM for both kinases. It shows at least >10 fold selectivity over a panel of 164 kinases. It is used as a potentiation cytotoxicity DNA-damaging agent. It is active in vivo. Synonyms: AZD 7762 hydrochloride; AZD7762 hydrochloride; AZD-7762 hydrochloride; 5-(3-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid N-[(S)-piperidin-3-yl]amide hydrochloride; 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-thiophenecarboxamide hydrochloride. Grades: ≥98% by HPLC. CAS No. 1246094-78-9. Molecular formula: C17H20FN4O2SCl. Mole weight: 398.88. | |
| AZD8055 | A potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. It inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition. Group: Biochemicals. Alternative Names: 5- [2, 4-Bis [ (3S) -3-methyl-4-morpholinyl] pyrido [2, 3-d] pyrimidin-7-yl] -2-methoxy Benzene methanol; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]- 2-methoxyphenyl] methanol; AZD 8055; [5- [2, 4-Bis ( (3S) -3-methylmorpholin-4-yl) pyrido [5, 6-e] pyrimidin-7-yl] -2-methoxyphenyl] methanol. Grades: Purified. CAS No. 1009298-09-2. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| AZD8055 | AZD8055 Inhibitor. Uses: Scientific use. Product Category: T1859. CAS No. 1009298-09-2. | |
| AZD-8055 | AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. Synonyms: AZD8055; AZD-8055; AZD 8055. Grades: 0.98. CAS No. 1009298-09-2. Molecular formula: C25H31N5O4. Mole weight: 465.554. | |
| AZD-8055 | AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC 50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2 [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1009298-09-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-10422. | |
| AZD8186 | AZD 8186 is a selective PI3Kβ/δ inhibitor (IC50= 0.003 μM for PI3Kβ, and 0.017 μM for PI3Kδ) with potential antineoplastic activity. It shows no significant binding against a panel of 442 other kinases when tested at a concentration of 10 μM and exhibits high oral efficacy in mouse cancer models. Synonyms: (R)-8-(1-((3,5-difluorophenyl)amino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide; AZD8186; AZD 8186; AZD-8186. CAS No. 1627494-13-6. Molecular formula: C24H25F2N3O4. Mole weight: 457.4. | |
| AZD8186 | AZD8186 is a PI3K inhibitor, which potently inhibits PI3Kβ (IC 50 =4 nM) and PI3Kδ (IC50 50 =12 nM) with selectivity over PI3Kα (IC 50 =35 nM) and PI3Kγ (IC 50 =675 nM). Uses: Scientific research. Group: Signaling pathways. CAS No. 1627494-13-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12330. | |
| AZD8186 | AZD8186 is and inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation. It also induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents. AZD8186 is currently under Phase I clinical trials. Group: Inhibitors. Alternative Names: AZD8186; AZD 8186; AZD-8186. CAS No. 1627494-13-6. Molecular formula: C24H25F2N3O4. Mole weight: 457.4. Appearance: Solid powder. Purity: >98%. IUPACName: (R)-8-(1-((3,5-difluorophenyl)amino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide. Canonical SMILES: O=C (N (C)C)C1=CC ([C@@H] (C)NC2=CC (F)=CC (F)=C2)=C3C (C (C=C (O3)N4CCOCC4)=O)=C1. Catalog: ACM1627494136. | |
| AZD8329 | AZD8329 is a potent, selective 11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor) with reduced acyl glucuronide liability. AZD8329 demonstrates to have improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability. Synonyms: AZD-8329; AZD 8329; 4-(4-((1r,3r,5r,7r)-adamantan-2-ylcarbamoyl)-5-(tert-butyl)-1H-pyrazol-1-yl)benzoic acid. Grades: 98%. CAS No. 1048668-70-7. Molecular formula: C25H31N3O3. Mole weight: 421.54. | |
| AZD-8330 | AZD8330 is an orally active, selective MEK inhibitor with potential antineoplastic activity. AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. Synonyms: AZD8330; AZD-8330; AZD 8330; ARRY424704; ARRY 424704; ARRY-424704; ARRY704; ARRY-704; ARRY 704. Grades: 0.98. CAS No. 869357-68-6. Molecular formula: C16H17FIN3O4. Mole weight: 461.232. | |
| AZD-8529 | AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes. Uses: Scientific research. Group: Signaling pathways. CAS No. 1092453-15-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107457. | |
| AZD-8529 mesylate | AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1314217-69-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107457A. | |
| AZD8797 | AZD8797 is a selective allosteric non-competitive modulator of the human CX3CR1 receptor (Ki = 3.9 nM), binding CX3CR1 and effecting G-protein signalling and β-arrestin recruitment in a biased way. AZD8797 has a 720 fold selectivity for CX3CR1 receptor over the CXCR2 receptor, a 246-fold selectivity versus hCCR1 and 187-fold versus hCCR2 and no significant antagonism of the CCR4, CCR5, CCR6, CXCR3, and CXCR5 receptors. Synonyms: AZD8797; AZD-8797; AZD 8797; (2R)-2-[[2-amino-5-[(1S)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol. CAS No. 911715-90-7. Molecular formula: C19H25N5OS2. Mole weight: 403.56. | |
| AZD-8835 | AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavailable inhibitor of the class I (PI3K) catalytic subunit alpha (PIK3CA). IC50: PI3Kδ= 5.7 nM, PI. Synonyms: 1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one AZD-8835 1620576-64-8 GTPL8915 SCHEMBL15877923 AZD8835 ZGRDYKFVDCFJCZ-UHFFFAOYSA-N BDBM185362 AZD 8835 AKOS027338670 compo. CAS No. 1620576-64-8. Molecular formula: C22H31N9O3. Mole weight: 469.54. | |
| AZD-8931 | Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. Synonyms: AZD8931; AZD 8931; Momelotinib; Sapitinib. Grades: 0.98. CAS No. 848942-61-0. Molecular formula: C23H25ClFN5O3. Mole weight: 473.933. | |
| AZD 9272 | AZD 9272 is a potent, long-acting and selective nervous system penetrant mGlu5 antagonist with IC50 values of 2.6 and 7.6 nM for rat and human receptors, respectively. It shows >3900-fold selectivity for mGlu5 over other mGlu receptors and shows discriminative effects in rats. It is orally bioavailable and brain penetrant. It has psychoactive and psychomimetic effects. Synonyms: AZD-9272; AZD 9272; AZD9272; 3-Fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile; 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole. Grades: ≥98% by HPLC. CAS No. 327056-26-8. Molecular formula: C14H6F2N4O. Mole weight: 284.22. | |
Our database is helping our users find suppliers everyday.
